Novo Nordisk CEO Sees Limited Scope for U.S. Price Increases
- Main growth driver will be introduction of new products
- Payers demanding rising rebates as drugs near patent expiries
This article is for subscribers only.
Novo Nordisk A/S expects that raising prices in the U.S. will become more challenging and and is banking on the introduction of a key new drug this month to grow in the world’s biggest pharmaceutical market.
Chief Executive Officer Lars Rebien Soerensen says the the Bagsvaerd, Denmark-based drugmaker has seen a change in the environment in the U.S. List price increases there will be “very limited” and will likely be offset by demands for rebates by payers, he told reporters on a conference call Wednesday.